Table 5—

Summary of studies examining the clinical effectiveness of macrolide therapy in post-transplant obliterative bronchiolitis

First author [ref.]Study designDrug regimenAdults/children nLength of studyBenefit?Adverse effects (treatment arm)
Gerhardt 61Prospective, open labelAzithromycin 250 mg daily for 5 days then three times weekly6Mean 13 weeks↑FEV1 (significant in 5/6 patients)Not examined
Verleden 62Prospective, open labelAzithromycin 250 mg daily for 5 days then alternate days8Min 12 weeks; max 36 weeks↑FEV1 (4 responders)Not examined
Shitrit 63Prospective, open label.Azithromycin 250 mg alternate days1110 monthsNo improvement in lung functionNot examined
Yates 64Retrospective, case seriesAzithromycin 250 mg alternate days20Mean 26 weeks↑FEV1 (sustained beyond 3 months in 12/17 patients)None
Khalid 65Prospective, open labelAzithromycin 500 mg q.i.d. for 3 days then 250 mg three times weekly8#12 weeks↑FEV1+FVCNone
Verleden 66Prospective, open labelAzithromycin 250 mg daily for 5 days then three times weekly1412 weeks↑FEV1 (6/14 responded; responders had higher neutrophil and IL-8 levels)Not examined
  • FEV1: forced expiratory volume in one second; min: minimum; max: maximum; FVC: forced vital capacity; IL: interleukin. #: allogenic bone marrow transplant.